Researchers at Washington University School of Medicine discovered that immune cells contributing to Alzheimer's-related brain damage may be activated in lymph nodes outside the brain before traveling into the nervous system. Blocking this pathway in mice dramatically reduced neurodegeneration and preserved cognitive abilities.
University of Florida researchers found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify abnormal sugar-tagging processes in the Alzheimer's brain, though the observational study does not prove causation.
Medical experts are sequencing plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening as first-line diagnostic tools for Alzheimer's disease, reserving confirmatory amyloid PET or CSF testing for inconclusive cases. Payer coverage for these biomarker tests has expanded, marking a shift in the diagnostic toolkit.
Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.
Clinical trials for major diseases are experiencing a critical shortage of participants, with only 7% of adult cancer patients in the U.S. enrolling in trials and Alzheimer's treatment studies facing similar global recruitment challenges despite new drug developments.
A small but growing body of research is examining whether Alzheimer's disease can be transmitted through certain medical procedures, exploring the concept of 'iatrogenic' AD. While the disease is not contagious through normal contact, scientists are investigating rare cases of potential medical transmission.
The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.
A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.
Two recent studies illuminate different cellular mechanisms in Parkinson's disease: one showing how alpha-synuclein protein clumps block waste recycling in neurons, and another revealing that the LRRK2-G2019S mutation disrupts development of astrocytes, the brain's support cells.
New research published in Neurology Open Access finds that maintaining normal blood pressure, avoiding type 2 diabetes, and not smoking between ages 45-68 is associated with nearly 13 more years of dementia-free life after age 55 compared to those with all three risk factors.
Researchers have overturned longstanding scientific dogma by discovering that beginning around age 50, the brain's memory center loses its longtime resident immune cells (microglia) and replaces them with more inflammatory immune cells derived from peripheral blood stem cells. This previously unrecognized migration may help explain how normal aging sets the stage for Alzheimer's disease and dementia.
Researchers have overturned long-held scientific understanding by discovering that aging human brains undergo a massive influx of peripheral blood-derived immune cells starting around age 50, replacing resident microglia with more inflammatory cells. This shift may help explain how normal aging sets the stage for Alzheimer's disease and dementia.
Scientists at Stanford University School of Medicine and University of California, San Francisco have identified a novel toxic mechanism in which hyperphosphorylated tau protein enters nerve cell mitochondria and reverses electron flow, potentially driving Alzheimer's disease and other neurodegenerative tauopathies.
Research published in Neurology on August 5, 2026 reveals that up to 85 percent of people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow disease progression.
Multiple breakthrough technologies for Alzheimer's detection are emerging, including a blood test that delivers results in 18 minutes, AI analysis of brain scans requiring minimal computing power, and machine learning that identifies dementia risk through sleep EEG patterns years before symptoms appear.
The LiBBY clinical trial found that a combination of CBD and THC rapidly and significantly reduced agitation in hospice-eligible dementia patients, with nearly 90% of participants showing behavioral improvement in the nationwide study.
A new study demonstrates that a blood test measuring p-tau217 levels can identify healthy older adults at high risk of developing Alzheimer's symptoms within five to 10 years, potentially enabling early intervention as prevention trials advance.
The World Health Organization has issued updated global guidelines on reducing cognitive decline and dementia risk, stating that up to 45% of dementia cases may be preventable or delayed by addressing modifiable risk factors throughout life.
An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.
ALZpath announced a global licensing deal with Abbott Laboratories to advance blood-based testing for Alzheimer's disease, joining the race to develop easier-to-use diagnostic options for the neurodegenerative condition.
The U.S. Food and Drug Administration approved an at-home starting dose of Eisai and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver rather than requiring initial doses in a clinical setting.
